Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: Prognostic significance

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1627-1631

  Kaklamanis, L ^a   Koukourakis, M I ^b   Leek, R ^a   Giatromanolaki, A ^a   Ritter, M ^c   Whitehouse, R ^b   Gatter, K C ^a   Harris, A L ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Interleukin 4 receptor associated MR6 molecule; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0029903471     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.599     Document Type: Article

References (34)

1. AL JABAARI B, LADYMAN HM, LARCHE M, SIVOLAPENCO GB, EPENETOS AA AND RITTER MA. (1989). Elevated expression of the interleukin-4 receptor in carcinoma: a target for immunotherapy? Br. J. Cancer, 59, 910-914.
2. BAMBOROUGH P, GRANT GH, HEDGECOCK CJ, WEST SP AND RICHARDS WG. (1993). A computer model of the interleukin-4/ receptor complex. Protein, 17, 11-19.
3. CORDELL JL, FALINI B, ERBER W, GHOSH A, ABDULAZIZ Z, MACDONALD S, PULFORD KAS, STEIN H AND MASON DY. (1984). Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP). J. Histochem. Cytochem., 32, 219.
4. DEBINSKI W, PURI RK, KRETMAN RJ AND PASTAN I. (1993). A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J. Biol. Chem., 268, 14065-14070.
5. DE MAAGD RA, MACKENZIE WA, SCHUURMAN H-J, RITTER MA, PRICE KM, BROEKHUIZEN R AND KATER L. (1985). The human monoclonal antiepithelial cell antibodies. Immunology, 54, 745-754.
6. EORTC BREAST COOPERATIVE GROUP. (1980). Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur. J. Cancer, 16, 1313-1315.
7. FRAKER PJ AND SPECK JC. (1978). Protein and cell membrane iodinations with a poorly soluble chloramide 1,3,4,6-tetrachloro-3 a, 6 a-diphenyl-glycolucil. Biochem. Biophys. Res. Commun., 80, 849-857.
8. GOLUMBEK PT, LAZENBY AJ, LEVITSKY HI, JAFFE LM, KARASUYAMA H, BAKER M AND PARDOLL DM. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254, 713-716.
9. HOON DS, OKUN E, BANEZ M, IRIE RF AND MORTON DL. (1991). Interleukin 4 alone and with gamma interferon or alpha tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res., 51, 5687-5693.
10. HOWARD M, FAZZAR J, HIFFIKER M, JOHNSON B, TAKATSU K, HAMAOKA T AND PAUL WE. (1982). Identification of a T-cell derived B-cell growth factor distinct from Interleukin-2. J. Exp. Med., 155, 914-923.
11. IZUHARA K, YANG G AND MIYAJIMA A. (1993). Structure of the IL-4 receptor and signal transduction mechanism of IL-4. Res. Immunol., 144, 584-590.
12. IMAMI N, LARCHE M AND RITTER MA. (1994). Inhibition of alloreactivity by mAb MR6: differential effects on IL-2- and IL-4 producing human T cells. Int. Immunol., 6, 1575-1584.
13. KAKLAMANIS L, GATTER KC, MORTENSEN N AND HARRIS AL. (1992). Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. Br. J. Cancer, 66, 712-716.
14. KAKLAMANIS L, LEEK R, KOUKOURAKIS M, GATTER KC AND HARRIS AL. (1995). Loss of TAP-1 transport protein and MHC-class I molecules in metastatic compared to primary breast cancer. Cancer Res., 55, 5191-5194.
15. LARCHE M, LAMB JR, O'HEHIR RE, IMAMI-SHITA N, ZANDERS E AND RITTER MA. (1988). A monoclonal antibody recognising the human interleukin-4 receptor. Immunology, 65, 617-622.
16. LORENZEN J, LEWIS CE, MCCRACKEN D, HORAK E, GREENAL M AND MCGEE JOD. (1991). Human tumor-associated NK cells secrete increase amounts of interferon-gamma and interleukin-4. Br. J. Cancer, 64, 457-462.
17. MAT IB, MOORS N, MELCHER D, FOXWELL BMJ AND RITTER MA. (1993). Comparison of MR6-Ag/IL-4 receptor complex and c-erB-2 antigen expression in breast tumours. In Mutant Oncogenes, Targets for Therapy, pp. 53-64. Chapman & Hall: London.
18. MAT I, LARCHE M, MELCHER D AND RITTER MA. (1990). Tumour-associated up-regulation of the IL-4 receptor complex. Br. J. Cancer, 62, Suppl. x, 96-98.
19. MONROE JG, HALDER S, PRYSTOWSKY MB AND LAMMIE P. (1988). Lymphokine regulation of inflammatory process: interleukin 4 stimulates fibroblast proliferation. Clin. Immunol. Immunopathol., 49, 292.
20. MURATA T, NOGUCHI PD AND PURI RK. (1996). Receptors for interleukin (IL)-4 do not associate with the common Á chain, and IL-4 induces the phosphorylation of Jak2 tyrosine kinase in human colon carcinoma cells. J. Biol. Chem., 270, 30829-30836.
21. NICHOLSON S, SAINSBURY JRC, NEEDHAM GK, CHAMBERS P, FARDON JR AND HARRIS AL. (1988). Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int. J. Cancer, 42, 36-41.
22. OBIRI NI, SIEGEL JP, VARRICCHIO F AND PURI RK. (1994). Expression of high affinity receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol., 95, 148-155.
23. O'HARA J AND PAUL WE. (1987). Receptors for B-cell stimulatory factor-1 expressed on cells of haemopoietic lineage. Nature, 325, 537.
24. OHIRA T, OHE Y AND SAIJO N. (1992). Induction of tumor immunity by cytokine cDNA transfected Lewis lung carcinoma. Nippon Kyobu Shikkan Gakkai Zasshi, 30(suppl.), 48-51.
25. PURI RK, OGATA M, LELAND P, FELDMAN GM, FITZGERALD D AND PASTAN I. (1991). Expression of high affinity interleukin 4 receptors on murin sarcoma cells and receptor mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Cancer Res., 51, 3011-3017.
26. THORNHILL MH AND HASKARD DO. (1990). IL-4 regulates endothelial cell activation by IL-1, tumor necrosis factor or IFNg. J. Immunol., 145, 865-872.
27. TOI M, HARRIS AL AND BICKNELL R. (1991). Interleukin-4 is a potent mitogen for capillary endothelium. Biochem. Biophys. Res. Commun., 174, 1287-1293.
28. TOI M, BICKNELL R AND HARRIS AL. (1992). Inhibition of colon and breast carcinoma cell growth by IL-4. Cancer Res., 52, 275-279.
29. TUNGEKAR G, TURLEY H, DUNNIL MS, GATTER KC, RITTER MA AND HARRIS AL. (1991). Interleukin-4 receptor expression on human lung tumors and normal lung. Cancer Res., 51, 261-264.
30. TUNGEKAR MF, GATTER KC AND RITTER MA. (1996). Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin-4 receptor (CD124). Br. J. Cancer, 73, 429-432.
31. TEPPER RI, PATTENGALE PK AND LEDER P. (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57, 503-512.
32. TOTPAL K AND AGGARWAL BB. (1991). Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. Cancer Res., 51, 4266-4270.
33. VON-GAUDECKER B, LARCHE M, SCHUURMAN HJ AND RITTER MA. (1989). Analysis of the fine distribution of thymic epithelial microenvironmental molecules by immuno-electron microscopy. Thymus, 13, 187-194.
34. ZALOOM Y AND GALLAGHER G. (1993). IL-2 inhibits the induction of systemic antitumour immunity by IL-4 in the peritumoral treatment of experimental melanoma. Anticancer Res., 13, 1081-1085.